Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6

BMC Cancer

Table 2 Downregulated proteins

Accession	Gene symbol	Protein	fold-change treated/control	FDR
P83731	RPL24	60S ribosomal protein L24	−4.14	0.00054
P61254	RPL26	60S ribosomal protein L26	−3.63	0.02751
P52272	HNRNPM	Heterogeneous nuclear ribonucleoprotein M	−3.24	0.00004
P18621	RPL17	60S ribosomal protein L17	−3.11	0.02499
O60506	SYNCRIP	Heterogeneous nuclear ribonucleoprotein Q	−2.89	0.04096
P62280	RPS11	40S ribosomal protein S11	−2.73	0.00944
P23284	PPIB	Peptidyl-prolyl cis-trans isomerase B	−2.41	0.02471
P16104	H2AFX	Histone H2AX	−2.36	0.00054
P13667	PDIA4	Protein disulfide-isomerase A4	−2.05	0.04384
P16104	H2AFZ	Histone H2A.Z	−1.99	0.00109
Q93077	HIST1H2AC	Histone H2A type 1-C	−1.92	0.00096
P04908	HIST1H2AB	Histone H2A type 1-B/E	−1.77	0.00165
P20671	HIST1H2AD	Histone H2A type 1-D	−1.75	0.01570
Q92841	DDX17	Probable ATP-dependent RNA helicase DDX17	−1.63	0.00109
Q9UKM9	RALY	RNA-binding protein Raly	−1.47	0.00531
Q9Y6E2	BZW2	Basic leucine zipper and W2 domain-containing protein 2	−1.31	0.00531

The table lists the proteins that showed to be downregulated (fold-change <−1.3) in LB24Dagi MM cells after 24 h of 10 μM D6 treatments (FDR <0.05). Proteins modulated also at the gene expression level are shown in bold characters [10]

ISSN: 1471-2407